dierks supplementary fig. s1 - cancer research...dierks supplementary fig. s1 itk syk ph k402r e42k...

Dierks Supplementary Fig. S1

ITK SYK

PHK402R

E42K

R29C

TH

wt

K402R (kinase deficient)

E42K

R29C (reduced phospholipid binding)

E42K (enhanced phospholipid binding)

Y323F (reduced Cbl binding)

E42K Y323F

Y323F

Y323F

Fig. S1 ITK-SYK constructs and point mutants The ITK-SYK fusion contains the pleckstrin homology domain (PH), which mediates its membrane localisation and the Tec-homology domain (TH) of ITK. The SYK fragment comprises the SYK tyrosine kinase (TK) domain. The ITK-SYK mutant K402R contains a point mutation within the SYK kinase domain (lysin > arginine), which induces loss of the SYK kinase activity. The point mutant R29C within the PH domain of ITK demonstrates reduced phospholipid-binding and therefore reduced membrane localization. E42K in contrast demonstrates enhanced phospholipid binding and therefore stronger membrane binding. The ITK-SYK mutant Y323F demonstrates reduced CBL binding due to the loss of the essential tyrosine residue as binding motif.

Dierks Supplementary Fig. S2 ITK-SYK sequence and point mutations M N N F I L L E E Q L I K K S Q Q K 18 ATG AAC AAC TTT ATC CTC CTG GAA GAA CAG CTC ATC AAG AAA TCC CAA CAA AAG 54 R R T S P S N F K V R>C F F V L T K A 36 AGA AGA ACT TCT CCC TCG AAC TTT AAA GTC CGC TTC TTC GTG TTA ACC AAA GCC 108 S L A Y F E>K D R H G K K R T L K G S 54 AGC CTG GCA TAC TTT GAA GAT CGT CAT GGG AAG AAG CGC ACG CTG AAG GGG TCC 162 I E L S R I K C V E I V K S D I S I 72 ATT GAG CTC TCC CGA ATC AAA TGT GTT GAG ATT GTG AAA AGT GAC ATC AGC ATC 216 P C H Y K Y P F Q V V H D N Y L L Y 90 CCA TGC CAC TAT AAA TAC CCG TTT CAG GTG GTG CAT GAC AAC TAC CTC CTA TAT 270 V F A P D R E S R Q R W V L A L K E 108 GTG TTT GCT CCA GAT CGT GAG AGC CGG CAG CGC TGG GTG CTG GCC CTT AAA GAA 324 E T R N N N S L V P K Y H P N F W M 126 GAA ACG AGG AAT AAT AAC AGT TTG GTG CCT AAA TAT CAT CCT AAT TTC TGG ATG 378 D G K W R C C S Q L E K L A T G C A 144 GAT GGG AAG TGG AGG TGC TGT TCT CAG CTG GAG AAG CTT GCA ACA GGC TGT GCC 432 Q Y D P T K N A S K K P L P P T P E 162 CAA TAT GAT CCA ACC AAG AAT GCT TCA AAG AAG CCT CTT CCT CCT ACT CCT GAA 486 D N R GAC AAC AGG S 306 TCC 918 S P A Q G N R Q E S T V S F N P Y>F E 324 TCC CCT GCC CAA GGG AAC CGG CAA GAG AGT ACT GTG TCA TTC AAT CCG TAT GAG 972 P E L A P W A A D K G P Q R E A L P 342 CCA GAA CTT GCA CCC TGG GCT GCA GAC AAA GGC CCC CAG AGA GAA GCC CTA CCC 1026 M D T E V Y E S P Y A D P E E I R P 360 ATG GAC ACA GAG GTG TAC GAG AGC CCC TAC GCG GAC CCT GAG GAG ATC AGG CCC 1080 K E V Y L D R K L L T L E D K E L G 378 AAG GAG GTT TAC CTG GAC CGA AAG CTG CTG ACG CTG GAA GAC AAA GAA CTG GGC 1134 S G N F G T V K K G Y Y Q M K K V V 396 TCT GGT AAT TTT GGA ACT GTG AAA AAG GGC TAC TAC CAA ATG AAA AAA GTT GTG 1188 K T V A V K>R I L K N E A N D P A L K 414 AAA ACC GTG GCT GTG AAA ATA CTG AAA AAC GAG GCC AAT GAC CCC GCT CTT AAA 1242 D E L L A E A N V M Q Q L D N P Y I 432 GAT GAG TTA TTA GCA GAA GCA AAT GTC ATG CAG CAG CTG GAC AAC CCG TAC ATC 1296 V R M I G I C E A E S W M L V M E M 450 GTG CGC ATG ATC GGG ATA TGC GAG GCC GAG TCC TGG ATG CTA GTT ATG GAG ATG 1350 A E L G P L N K Y L Q Q N R H V K D 468 GCA GAA CTT GGT CCC CTC AAT AAG TAT TTG CAG CAG AAC AGA CAT GTC AAG GAT 1404 K N I I E L V H Q V S M G M K Y L E 486 AAG AAC ATC ATA GAA CTG GTT CAT CAG GTT TCC ATG GGC ATG AAG TAC TTG GAG 1458 E S N F V H R D L A A R N V L L V T 504 GAG AGC AAT TTT GTG CAC AGA GAT CTG GCT GCA AGA AAT GTG TTG CTA GTT ACC 1512 Q H Y A K I S D F G L S K A L R A D 522 CAA CAT TAT GCC AAG ATC AGT GAT TTC GGA CTC TCC AAA GCA CTG CGT GCT GAT 1566

E N Y Y K A Q T H G K W P V K W Y A 540 GAA AAC TAC TAC AAG GCC CAG ACC CAT GGA AAG TGG CCT GTC AAG TGG TAC GCT 1620 P E C I N Y Y K F S S K S D V W S F 558 CCG GAA TGC ATC AAC TAC TAC AAG TTC TCC AGC AAA AGC GAT GTC TGG AGC TTT 1674 G V L M W E A F S Y G Q K P Y R G M 576 GGA GTG TTG ATG TGG GAA GCA TTC TCC TAT GGG CAG AAG CCA TAT CGA GGG ATG 1728 K G S E V T A M L E K G E R M G C P 594 AAA GGA AGT GAA GTC ACC GCT ATG TTA GAG AAA GGA GAG CGG ATG GGG TGC CCT 1782 A G C P R E M Y D L M N L C W T Y D 612 GCA GGG TGT CCA AGA GAG ATG TAC GAT CTC ATG AAT CTG TGC TGG ACA TAC GAT 1836 V E N R P G F A A V E L R L R N Y Y 630 GTG GAA AAC AGG CCC GGA TTC GCA GCA GTG GAA CTG CGG CTG CGC AAT TAC TAC 1890 Y D V V N * 636 TAT GAC GTG GTG AAC TAA 1908

Fig. S2 ITK-SYK sequence and point mutations As described by Streubel et al., the ITK-SYK fusion contains 165 amino acids (495 base pairs) from the ITK gene and 331 amino acids (993 base pairs) from the SYK tyrosine kinase. The sequence in black contains the ITK-part of the sequence and the sequence in red the SYK part of the sequence. The point mutantions inserted to generate the different loss or gain of function constructs are shown within the sequence.

-0.35

-0.30

-0.25

-0.20

-0.15

-0.10

-0.05

0.00

0.05

0.10

0.15

0.20

d 0 d 7 d 14 d 21 d 28 d 35 d 42

Per

cen

tag

e o

f sta

rt w

eig

ht

pMSCV GFP

pMSCV ITK-SYKGFP

Dierks Supplementary Fig. S3 Fig. S3 Mouse weight in mice transplanted with ITK-SYK-positive bone marrow Average mouse weight of mice transplanted with bone marrow infected with a pMSCV/IRES/GFP control vector or pMSCV/ITK-SYK/IRES/GFP (8 mice per group, ±SD).


GFP ITK-SYK

Fig. S4 Enlarged lymph nodes in ITK-SYK-positive mice Representable examples for lymph nodes in mice transplanted with bone marrow either infected with a GFP control virus or an ITK-SYK/GFP virus 4 weeks after transplantation. All ITK-SYK positive mice had enlarged lymph nodes compared to the control group.

Dierks, Supplementary Fig. S5 Fig. S5 Spleen infiltration with CD3+ cells in ITK-SYK-positive mice IHC staining for CD3 in spleens from one representative ITK-SYK pos. diseased mouse demonstrates massive infiltration of the spleen with CD3 pos. T-cells with expansion of T-cells into the red pulpa. (photomicrographs with 20-fold and 40-fold magnification)


Fig. S6 Percentage of regulatory T-cells in spleen and bone marrow of transplanted mice Isolation from white blood cells from the spleen and the bone marrow from mice either transplanted with the pMSCV/GFP control vector or the pMSCV/ITK-SYK/GFP vector 5 weeks after transplantation. The graphs show the percentage of CD4+CD25+Foxp3+ regulatory T-cells within the GFP-positive or GFP-negative population in control versus ITK-SYK mice in the spleen (left) or bone marrow (right). The percentage of regulatory T-cells in ITK-SYK mice is not significantly enhanced in bone marrow and spleens compared to control mice (p> 0,05) .

0

10

20

30

40

50

60

70

80

90

control ITK-SYK

Spleen

%ig

e o

f CD

3 p

os.

cel

ls

with

in W

BC

s

GFP-

GFP+

0

5

10

15

20

25

30

35

40

45

control ITK-SYK

Bone marrow

%ig

e o

f CD

3 p

os.

cel

ls

with

in W

BC

s

GFP-

GFP+


Fig. S7 Number of CD3-positive T-cells in transplanted mice Isolation from white blood cells from the spleen and the bone marrow from mice either transplanted with the pMSCV/GFP control vector or the pMSCV/ITK-SYK/GFP vector 5 weeks after transplantation. The graphs show the percentage of CD3 positive T-cells within the GFP-positive or GFP-negative population in control versus ITK-SYK mice in the spleen (left) or bone marrow (right).

Spleen

0

5

10

15

20

25

30

35

40

45

control spleen ITK-SYK spleen

GFP-negative cells

Per

cen

tag

e o

f T

-cel

l su

bse

ts

wit

hin

wh

ole

cel

ls

CD4-CD8-

CD4+CD8+

CD8+

CD4+

Bone marrow

0

2

46

8

10

12

1416

18

20

control BM ITK-SYK BM

GFP-negative cells

Per

cen

tag

e o

f T

-cel

l su

bse

ts

wit

hin

wh

ole

cel

ls

CD4-CD8-

CD4+CD8+

CD8+

CD4+


Fig. S8 T-cell subsets within the GFP-negative T-cell population Isolation from white blood cells from the spleen and the bone marrow from mice either transplanted with the pMSCV/GFP control vector or the pMSCV/ITK-SYK/GFP vector 5 weeks after transplantation. The graphs show the average percentage of the different T-cell subsets (CD4+, CD8+, CD4+CD8+, CD4-CD8-) within the GFP-negative population in control versus ITK-SYK mice in the spleen (left) or bone marrow (right). The percentage of CD3-positive cells within the GFP-negative population in ITK-SYK pos. mice is significantly reduced compared to control mice in the spleen (p < 0,05 unpaired T-Test) and shows a tendency towards reduction in the bone marrow (no statistical significancp > 0,05).

0

10

20

30

40

50

60

control ITK-SYK

%ig

e o

f B

220+

B-c

ells

wit

hin

WB

Cs

in t

he

sple

en GFP-

GFP+


Fig. S9 Number of B220+ B-cells in the spleen of transplanted mice Isolation from white blood cells from the spleen and the bone marrow from mice either transplanted with the pMSCV/GFP control vector or the pMSCV/ITK-SYK/GFP vector 5 weeks after transplantation. Detection of B220 positive cells by flow cytometry. The graphs show the average percentage of the B-cells within spleen cells isolated from control mice or ITK-SYK positive mice.

Retransplantation of ITK-SYK-pos. cells

0

1

2

3

4

5

6

0 10 20 30 40 50

survival days

surv

ivin

g m

ice

bone marrow cells spleen cells


Fig. S10 Retransplantation of ITK-SYK-positive cells Retransplantation of bone marrow and spleen cells isolated from ITK-SYK-positive mice into irradiated recipients. Figure shows survival of secondary recipients transplanted with either complete bone marrow or complete spleen cells isolated from diseased primary recipients.

Tx1Mouse 2

Tx2 M2Mouse A

Tx2 M2Mouse B

Tx2 M2Mouse C

Vbeta 01 Vbeta 06

Tx1Mouse 2

Tx2 M2Mouse A

Tx2 M2Mouse B

Tx2 M2Mouse C

Vbeta 01 Vbeta 06

Tx1Mouse 1

Tx2 M1Mouse A

Vbeta 20

Tx1Mouse 1

Tx2 M1Mouse A

Vbeta 20

Dierks Supplementary Fig. S11 Fig. S11 TCR V� spectratyping of ITK-SYK positive T-cells reveals clonal events in secondary recipient mice Spectratyping for the T-cell receptor repertoire using primers for V� 1-20 was performed in primary (Transplantation1 = Tx1) and secondary (Transplantation 2 = Tx2) recipients of ITK-SYK/GFP positive bone marrow. Spleen cells were harvested from diseased mice. For mice with a spleen infiltration of below 50 % ITK-SYK/GFP pos. cells, the GFP positive cells were purified by FACS. This was done to avoid overlooking clonal events via cross contamination with ITK-SYK negative T-cells (Tx2 M2 Mouse C, Tx2 M1 Mouse A). All primary recipients developed a polyclonal disease (Tx1 Mouse 1, Tx1 Mouse 2). In contrast, we observed a mono/biclonal disease in 3 out of 4 secondary recipients (Tx2 M2 Mouse A, Tx2 M1 Mouse A, Tx2 M2 Mouse C).A TCR V� spectratyping for primary recipient (Tx1 Mouse 1) and for the secondary recipient (Tx2 M1 Mouse A), which received bone marrow from this diseased primary recipient. Clonal event in secondary recipient was found in Vbeta 20. B TCR V� spectratyping for primary recipient Tx1 Mouse 2 and its secondary recipients (Tx2 M2 Mouse A/B/C). Clonal event in secondary recipients were found in Vbeta 1 and Vbeta 6. Mouse C had a clonal peak in Vbeta 1 and Vbeta 6, which can be interpreted as either biclonal disease or monoclonal disease with biallelic rearrangement. Tx1 = Transplantation 1 = primary recipients Tx2 = Transplantation 1 = secondary recipients Mouse 1/2 = M1/2 = number of primary recipient mouse Mouse A/B/C = number of secondary recipient mouse

A B

0

5

10

15

20

25

30

35

40

45

50

control Spleen

ITK-SYKK402RSpleen

control BM ITK-SYKK402R BMP

erce

nta

ge

of

T-c

ell

sub

sets

wit

hin

GF

P-

po

siti

ve n

ucl

ear

cell

s

CD4-CD8-

CD4+CD8+

CD8+

CD4+


Fig. S11 T-cell subsets within the GFP-positive nuclear cells in control mice versus mice transplanted with kinase-deficient ITK-SYK Isolation from nuclear cells from the spleen and the bone marrow from mice either transplanted with the pMSCV/GFP control vector or the pMSCV/ITK-SYK K402R/GFP vector 5 weeks after transplantation. Analysis of T-cell subsets was performed using flow cytometry. The graphs show the average percentage of the different T-cell subsets (CD4+, CD8+, CD4+CD8+, CD4-CD8-) within the GFP-positive population in control versus ITK-SYK K402R mice in the spleen or bone marrow.

GFP wt R29C E42K K402R

GFP

CD

11b

CD

3

Dierks Supplementary Fig. S13 A B Fig. S13 Increased inflammation in mice carrying the cytoplasmic localized mutant ITK-SYK R29C A Unspecific signs of inflammation 4 weeks after transplantation (swollen tail, swollen and red nose, diarrhea, ear infiltration). B (upper panel) CD3-PECy7/GFP measurement of spleen cells 3 weeks after transplantation. CD3/GFP double positive population appears in all mice transplanted with ITK-SYK pos. bone marrow with intact kinase activity. (lower panel) Unspecific infiltration of CD11b-positive/GFP-negative myeloid cells into the spleens of mice transplanted with ITK-SYK wt and the 2 mutants with intact kinase activity.

signs of inflammation

0.0%

20.0%

40.0%

60.0%

80.0%

GFPcontrol

ITK-Sykw t

ITK-SykR29C

ITK-SykE42K

ITK-SykK402R

%ig

e o

f m

ice

wit

h

infl

amm

atio

n


0

10

20

30

40

50

60

70

80

90

100

110

vehicle Curcumin 50mg/kg bid

Curcumin 100mg/kg bid

splenic CD3+/GFP+ T-cells

Per

cen

tag

e o

f sp

len

ic C

D3+

/GF

P+

T-

cells

co

mp

ared

to

veh

icle

co

ntr

ol

Fig. S14 Curcumin induced reduction of ITK-SYK positive T-cells in the spleen Flow cytometry analysis of ITK-SYK/GFP+CD3+ population in the spleens of treated mice. Graph shows percentage of CD3+/ITK-SYK+ T-cells compared to vehicle treated mice. Statistical significance for both treatment groups (unpaired t-test, P < 0,05).

p-Syk Tyr 525 staining

Vehicle 1

Vehicle 2

Curcumine 50 mg/kg bid 1




In-vivo treatment (GFP pos. cells)

p-Syk Tyr 525 staining

Vehicle 1

Vehicle 2





Vehicle 1

Vehicle 2





In-vivo treatment (GFP pos. cells)

Dierks Supplementary Fig. S15 Fig. S15 Reduced ITK-SYK phosphorylation in Curcumin treated mice Detection of phospho-SYK Tyr525 by flow cytometry in the ITK-SYK/GFP positive T-cell population after treatment of mice with Curcumin for 14 days in vivo. Graph shows 2 representative examples per treatment group.

0

10

20

30

40

50

60

70

80

90

100

110


Curcumin 100mg/kg bid

Spleen weight

wei

gh

t in

mg

0

10

20

30

40

50

60

70

80

90

100

110


Curcumin100 mg/kg

bid

splenic CD3+ T-cells

Per

cent

age

of s

plen

ic C

D3+

/GFP

+ T

cells

com

pare

d to

veh

icle

con

trol


Fig. S16 Curcumin treatment of healthy Balb/c mice Spleen weight comparison of Balb/c females treated with vehicle or Curcumin for 14 days. No statistical difference was detected in between the different treatment groups (unpaired t-test, P > 0,05). Flow cytometry analysis of CD3+ population in the spleens of treated mice. Graph shows percentage of CD3+ T-cells compared to vehicle treated mice. Differences are not statistically significant for both treatment groups (unpaired t-test, P > 0,05).

dierks supplementary fig. s1 - cancer research...dierks supplementary fig. s1 itk syk ph k402r e42k...

Documents